BIOD 102 (6) Questions with CORRECT Answers
Question:
New Drug Approval (NDA) 2 months - 7 years
Answer:
Clinal data from trials are examined. If the drug seems to have reasonable
benefit, the trial can continue into postmarketing studies. Scientists and
practictioners are given a chance to remediate concerns, and then the developement
process can begin.
Question:
Drug Safety CAtegories A, B, C, D, X
Answer:
the presence of unpleasant physical withdrawal symptoms
Question:
Drug Safety CAtegories A, B, C, D, X
Answer:
Refers to the potential harm a drug can cause to a fetus if the mother ingests it
during pregnancy. A is the lowest risk of harm, X is the greatest risk. Most drugs
are not evaluated during pregnancy because of the ethical considerations that
arise with the potential harm to a developing fetus.
Question:
A drug eliciting its effects on its target organ is an example of which step of
pharmacokinetics?
Answer:
Distribution
Question:
Inactivation of a drug occurs at which step of pharmacokinetics?
Answer:
Metabolism
Question:
New Drug Approval (NDA) 2 months - 7 years
Answer:
Clinal data from trials are examined. If the drug seems to have reasonable
benefit, the trial can continue into postmarketing studies. Scientists and
practictioners are given a chance to remediate concerns, and then the developement
process can begin.
Question:
Drug Safety CAtegories A, B, C, D, X
Answer:
the presence of unpleasant physical withdrawal symptoms
Question:
Drug Safety CAtegories A, B, C, D, X
Answer:
Refers to the potential harm a drug can cause to a fetus if the mother ingests it
during pregnancy. A is the lowest risk of harm, X is the greatest risk. Most drugs
are not evaluated during pregnancy because of the ethical considerations that
arise with the potential harm to a developing fetus.
Question:
A drug eliciting its effects on its target organ is an example of which step of
pharmacokinetics?
Answer:
Distribution
Question:
Inactivation of a drug occurs at which step of pharmacokinetics?
Answer:
Metabolism
